In the
carrageenin-induced
edema test in rats, the anti-inflammatory activity of
SL-573 was 1.6 times as potent as those of
phenylbutazone (PB) and
ibuprofen (IP), 3.3 times as potent as that of
mefenamic acid (MF) and 6.7 times as potent as that of
mepirizole (MP). In the yeast-induced
edema test in rats,
SL-573 showed equipotent activity with IP, the activity of which was 4 times as potent as that of MP. In the
dextran-induced
edema test in rats, the anti-inflammatory activity of
SL-573 was significantly higher than those of IP and MP.
SL-573 showed no anti-inflammatory activity in the
formalin-induced
edema test in rats in the same way as seen with IP and MP.
SL-573 markedly inhibited the increase in capillary permeability in mice induced by intraperitoneal administration of
acetic acid, and its activity was 12 times as potent as that of PB and 17 times as potent as that of MF.
SL-573 showed anti-
granuloma activity neither systemically nor locally.
SL-573 showed equi-potent activity with PB in the
adjuvant arthritis test in rats and had little effect on the healing process of the skin
wound in rats. The effect of
SL-573 on the
carrageenin-induced
edema was not diminished in the adrenalectomized rats. The gastric
bleeding effect of
SL-573 was significantly weaker than that usually seen in nonsteroidal anti-inflammatory drugs.
SL-573 did not induce
intestinal perforation even at the high dose of 800 mg/kg. Additionally,
SL-573 showed a protective effect on the
indomethacin-induced intestinal lesions. These pharmacological profiles of
SL-573 were considered to be quite characteristic as compared with those of known
nonsteroidal anti-inflammatory agents.